Intelligent Pan-Antiallergy Vaccine Development System

A novel system integrating AI, IoT, blockchain, and nano-particle technologies to develop personalized, targeted, and effective pan-antiallergy vaccines

The original pan-antiallergy vaccine patent, while a significant breakthrough, has limitations in terms of scalability, personalization, and real-time monitoring. The new inventive concept addresses these limitations by combining the patented protein construct with advanced technologies to create a more powerful and adaptive system.

The system consists of a blockchain-based database for storing and managing genetic data of IgE motif segments, a machine learning module for predicting optimal scaffold segments, and an IoT-enabled sensor for detecting and monitoring IgE levels in subjects. The system integrates with an AI-powered recommendation engine to select optimal protein constructs for personalized vaccines. Additionally, a nano-particle carrier system is used for targeted delivery of the protein construct to immune cells. The system also includes a cloud-based analytics platform for real-time monitoring of vaccine efficacy.

The new claims introduce the integration of AI, IoT, blockchain, and nano-particle technologies with the patented protein construct, enabling personalized, targeted, and adaptive pan-antiallergy vaccines. This synergistic combination is novel and non-obvious compared to the original patent.

Alternative embodiments include using different AI models, IoT devices, or blockchain protocols. Variations could include integrating additional technologies, such as CRISPR gene editing, or applying the system to other types of vaccines or immunotherapies.

The Intelligent Pan-Antiallergy Vaccine Development System has significant commercial potential in the vaccine and immunotherapy markets, with potential applications in personalized medicine, precision health, and disease prevention.